- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Conshohocken Today
By the People, for the People
Madrigal Pharma grants inducement equity awards
20 new non-executive employees receive stock options and restricted stock units
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
Madrigal Pharmaceuticals, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The new employees received, in the aggregate, options to purchase 789 shares of Madrigal's common stock, and in the aggregate 6,882 time-based restricted stock units.
Why it matters
The equity awards are part of Madrigal's efforts to attract and retain top talent as it continues to develop its lead medication, Rezdiffra, for the treatment of MASH, a liver disease with high unmet medical need. Inducement awards are a common practice in the biotech industry to incentivize new hires.
The details
The options have an exercise price of $432.00 per share, which is equal to the closing price of the company's common stock on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter. The restricted stock units also vest over four years, with 25% vesting on each anniversary of the grant date.
- The equity awards were granted on March 1, 2026.
The players
Madrigal Pharmaceuticals, Inc.
A biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
Rezdiffra (resmetirom)
Madrigal's lead medication, a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3).
The takeaway
Madrigal's equity inducement awards demonstrate the company's commitment to building a talented team as it continues to advance its lead MASH treatment, Rezdiffra, through clinical development and regulatory approval.
